Rexahn seeks to establish strategic alliances and partnerships that complement our expertise in oncology product development with important scientific, clinical and business capabilities. These alliances may incorporate our various technology platforms and products. (RX-3117, RX-5902 and RX-0201)

We continually review opportunities to in-license and advance compounds in oncology that have value creating potential and will strengthen our clinical development pipeline.

For additional information about our products or to send us information about your products and technologies, please contact: